Tectochrysin: A Comprehensive Encyclopedic Reference
1. Identity and Chemical Characterization
Chemical Names and Classification
Tectochrysin is a naturally occurring flavone — a subclass of the broader flavonoid family — characterized by a methylated hydroxyl group at position 7 of the flavone backbone. It is formally defined as a monohydroxyflavone substituted by a hydroxy group at position 4 and a methoxy group at position 7. Its principal systematic chemical names include 5-Hydroxy-7-methoxyflavone, 5-Hydroxy-7-methoxy-2-phenyl-4H-chromen-4-one, and 7-O-methylchrysin. Additional synonyms found in the chemical literature include 4H-1-Benzopyran-4-one, 5-hydroxy-7-methoxy-2-phenyl-; Techtochrysin; and 7-Methoxy-5-hydroxyflavone. The CAS registry number for tectochrysin is 520-28-5. Structurally, flavonoids constitute a broad class of naturally occurring polyphenolic compounds widely present in various plants, fruits, and vegetables, sharing a common flavone backbone composed of two aromatic rings (A and B) connected by a three-carbon bridge forming a heterocyclic ring (C). Tectochrysin represents the 7-O-methylated derivative of chrysin (5,7-dihydroxyflavone), differing from its parent compound by the substitution of the 7-hydroxyl group with a methoxy group.
Natural Sources and Botanical Origins
Tectochrysin can be isolated from propolis, Alpinia oxyphylla Miq., and Lychnophora markgravii. Among these, Alpinia oxyphylla Miq. (family Zingiberaceae, commonly known in Chinese as Yizhi) is by far the most studied and pharmacologically characterized botanical source. Tectochrysin was found to be the second most abundant flavonoid concentrated in the fruit capsules of A. oxyphylla at approximately 0.2 mg/g (0.02%). The fruits of A. oxyphylla contain many kinds of chemical constituents, including essential oils, sesquiterpenes, flavones, diarylheptanoids, glycosides, and steroids.
Alpinia oxyphylla Miquel has been used in China for centuries as both a food and medicinal substance. As one of the "four famous south medicines" of China, it is widely used as a tonic, aphrodisiac, and anti-polyuric agent according to the Chinese Pharmacopoeia. In Hainan province, A. oxyphylla is often applied as a health-care food. Beyond these principal sources, tectochrysin is also described more broadly as a flavonoid antioxidant found in plants and fruits. Tectochrysin is also found as a constituent of propolis (bee glue), the resinous material produced by honey bees from botanical exudates, which contributes to its occurrence in honey bee products from various geographic regions.
Common Forms and Preparations
In research settings, tectochrysin is isolated from plant material using a range of analytical and preparative methods. Isolation methods that have been applied include microwave-assisted extraction, response surface methods, chiral high-performance liquid chromatography–multiple reaction monitoring–mass spectrometry (HPLC-MRM-MS), ultra-high-performance liquid chromatography–quadrupole–electrostatic field Orbitrap high-resolution mass spectrometry (UPLC-Orbitrap-HRMS), UPLC-MS/MS, hot water leaching, and ethanol leaching. As a pure reference compound, tectochrysin is commercially distributed for laboratory use as a dry powder or dissolved in organic solvents (e.g., DMSO). It is not yet standardized in any major official pharmacopeia monograph as a stand-alone ingredient. In traditional preparations, the fruit of A. oxyphylla — which naturally contains tectochrysin — is most commonly employed as an ethanol or aqueous extract rather than as an isolated compound.
2. Traditional and Historical Use
Traditional Chinese Medicine
The traditional use of tectochrysin is largely derived from its occurrence in the fruits of Alpinia oxyphylla, which has a long and well-documented history within the Traditional Chinese Medicine (TCM) system. Alpinia oxyphylla Miq. (Yizhi), a well-known health food and traditional Chinese medicine, is widely distributed in Southern China and is traditionally applied to treat intestinal and urethral disorders. Tectochrysin, as a constituent of Alpinia oxyphylla Miq., has been traditionally associated with the treatment of diarrhea, salivation, diuresis, and dementia. Alpiniae oxyphyllae Fructus (AOF), derived from the dried and mature fruits of the Zingiberaceae plant Alpinia oxyphylla Miq., is a choice in traditional Chinese medicine to treat Alzheimer's disease, having reportedly demonstrated good effects and been used for a long time.
Recent pharmacological studies have corroborated the traditional use of AOF by demonstrating its potent activities in modulating multiple signaling pathways associated with β-amyloid deposition, tau protein phosphorylation, chronic inflammation, and oxidative stress. In TCM, the preparation is principally from the dried, mature fruit, processed by decoction or ethanol extraction. The broader plant extract (not only the isolated flavonoid tectochrysin) has historically been the vehicle of these traditional applications.
Other Ethnobotanical Contexts
Phytochemical analysis of propolis, Alpinia oxyphylla, and Lychnophora markgravii has led to the isolation of tectochrysin. The presence of tectochrysin in propolis ties it, indirectly, to the widespread traditional use of propolis across many cultures — including ancient Egypt, Greece, and various folk medicine traditions of Europe, the Middle East, and South America — where propolis was used as an antimicrobial, wound-healing, and anti-inflammatory substance. However, the specific attribution of any traditional propolis use to tectochrysin specifically (rather than to propolis as a whole or to other well-characterized propolis constituents such as caffeic acid phenethyl ester) has not been established in the ethnobotanical literature available.
3. Key Constituents, Chemistry, and Mechanisms of Action
Chemical Structure and Relationship to Chrysin
Tectochrysin belongs to the flavone class and is the 7-O-methyl ether of chrysin. The key structural distinction between the two is the methyl group at the 7-position, which converts the free hydroxyl of chrysin to a methoxy group. This methylation generally increases lipophilicity, potentially affecting the compound's absorption, distribution, and metabolism relative to chrysin. The biological activity of related flavonoids is primarily attributed to the presence of hydroxyl groups, which facilitate the neutralization of free radicals and the modulation of intracellular signaling pathways. Tectochrysin retains the free 5-hydroxyl group on the A-ring, which is considered important for chelation of metal ions and for interactions with target proteins, while the 7-methoxy group may modulate its selectivity for certain molecular targets compared to chrysin.
Antioxidant Mechanisms
Tectochrysin has demonstrated antioxidant, anti-inflammatory, anti-cancer, anti-bacterial, anti-diarrheal, hepatoprotective, and neuroprotective effects in preclinical research. Its antioxidant activity operates through multiple mechanisms. In animal studies, tectochrysin has been shown to decrease concentrations of malondialdehyde (a marker of lipid peroxidation) and increase the activities of superoxide dismutase and glutathione peroxidase in hippocampal and cortical tissue. Tectochrysin has also been shown to restore reduced glutathione (GSH) and superoxide dismutase (SOD) levels, inhibit malondialdehyde (MDA) content, and activate the HO-1/Nrf2 pathway — a master transcriptional regulator of the cellular antioxidant response.
Anti-inflammatory Mechanisms
Several distinct molecular pathways through which tectochrysin exerts anti-inflammatory effects have been characterized in preclinical studies. Tectochrysin inhibits extracellular signal-related kinase 1/2 (ERK1/2) phosphorylation and sequentially suppresses downstream inducible nitric oxide synthase (iNOS), tumor necrosis factor-α (TNF-α), and IL-6 transcription in LPS-primed macrophages; an enzyme reaction study further confirms that tectochrysin exerts its inhibitory effect on ERK1/2 phosphorylation by inactivating phosphorylated MEK1/2. Tectochrysin also suppresses inflammatory mediator release in peritoneal lavage fluid and in the serum of LPS-induced endotoxemia mice.
In addition to the MEK/ERK axis, tectochrysin modulates the NF-κB transcription factor pathway. Tectochrysin treatment inhibits the activity of NF-κB, and a docking model has indicated that tectochrysin binds directly to the p50 subunit of NF-κB. Another study showed that tectochrysin suppresses inflammatory activation by targeting the macrophage JAK3/STAT3 signaling pathway, thereby improving rheumatoid arthritis in preclinical models. In periodontitis research, tectochrysin reduced alveolar bone loss, promoted new bone formation, and inhibited osteoclast formation in periodontitis rats; it decreased the number of inflammatory cells and the levels of IL-1β, IL-6, and TNF-α, and restored the Arg-1/iNOS ratio, indicating M2 macrophage polarization, while inhibiting the NF-κB pathway.
Anticancer Mechanisms
Tectochrysin has been demonstrated to induce apoptosis in prostate cancer cells by affecting the TNF-α-related apoptosis-inducing ligand (TRAIL) and phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) signaling pathways, suppressing NF-κB activity, and increasing the expression levels of death receptors in colon cancer cells. In colon cancer studies, tectochrysin suppressed the growth of SW480 and HCT116 human colon cancer cells, significantly increased expression of death receptor 3 (DR3), DR4, and Fas, and increased pro-apoptotic proteins. Tectochrysin leads to apoptotic cell death in colon cancer cells through activation of death receptor expression via the inhibition of NF-κB.
Regarding multidrug resistance, tectochrysin has been identified as a potent inhibitor of the ATP-binding cassette transporter ABCG2. Further work demonstrated that tectochrysin is not a substrate of P-glycoprotein (P-gp), nor does it affect the expression of this transporter; instead, it noncompetitively inhibits the efflux of rhodamine 123 and doxorubicin through P-gp. This dual transporter-inhibitory activity — acting on both ABCG2 and P-gp — is mechanistically relevant to the reversal of multidrug resistance in cancer cells.
Neuroprotective Mechanisms
In Alzheimer's disease models, administration of tectochrysin at 140 µg/kg by intracerebroventricular injection in Aβ1-42-induced AD mice resulted in improved spatial memory performance and down-regulated expressions of β-secretase and accumulation of Aβ1-42 in brain tissues. Tectochrysin also decreased the concentration of malondialdehyde and total cholinesterase, and increased activities of both antioxidant superoxide dismutase and glutathione peroxidase in hippocampal and cortical tissues.
Aging and Longevity Pathways
Tectochrysin could not extend the lifespan of C. elegans mutants from genes daf-2, daf-16, eat-2, aak-2, skn-1, and hsf-1; it increased the expression of DAF-16-regulated genes, and the extension of lifespan by tectochrysin requires FOXO/DAF-16 and HSF-1. This dependency on the conserved insulin/IGF-1 signaling pathway (with FOXO/DAF-16 as a central effector) links tectochrysin to a well-characterized longevity mechanism that is also operative in mammals.
Cardioprotective Mechanisms
Angiotensin II (Ang II)-induced cardiac inflammation plays a pivotal role in the pathogenesis of pathological cardiac hypertrophy and hypertension-related heart failure; tectochrysin is a flavonoid natural compound exhibiting significant anti-inflammatory activity, although the role of tectochrysin in hypertensive heart failure and its molecular targets had remained unclear. Recent work in 2026 addressed this: in vivo and in vitro experiments demonstrated that tectochrysin inhibits activation of the STING-NFκB pathway, and use of the STING inhibitor H151 further confirmed that STING is a critical mediator through which tectochrysin exerts its cardioprotective effects.
4. Scientific Evidence by Health Area
4.1 Neuroprotection and Alzheimer's Disease
Evidence level: Preclinical (animal and in vitro only — no human clinical trials identified).
The most extensively studied area for tectochrysin in recent years is neuroprotection, specifically in the context of Alzheimer's disease (AD). Tectochrysin is a flavonoid compound isolated from Alpinia oxyphylla Miq. that has been traditionally used for treatment of diarrhea, salivation, diuresis, and dementia; model mice with AD induced by intracerebroventricular injection of Aβ1-42 were used to determine the role of tectochrysin on memory retrieval. The results revealed that AD mice receiving intracerebroventricular injection of tectochrysin at 140 µg/kg showed improved spatial memory performance and down-regulated expressions of β-secretase and accumulation of Aβ1-42 in brain tissues; tectochrysin also decreased the concentration of malondialdehyde and total cholinesterase, and increased activities of both antioxidant superoxide dismutase and glutathione peroxidase in hippocampal and cortex.
The pharmacokinetic study by Zhao et al. (2018), using UPLC-MS/MS, assessed Alpinia oxyphylla fruit ethanol extract containing tectochrysin given orally to both normal and dementia rats. Flavonoids in A. oxyphylla showed low plasma levels because they mainly formed mono-glucuronide metabolites, making it difficult to determine free flavonoids in plasma. When the validated method was applied to a comparative pharmacokinetic study after oral administration of A. oxyphylla fruit ethanol extract, the area under the curve (AUC) and peak plasma concentration (Cmax) of both chrysin and tectochrysin were remarkably increased in dementia rats compared to normal rats. This differential pharmacokinetic profile in disease states is scientifically significant and suggests altered metabolic handling in neurodegeneration.
All neuroprotection evidence for tectochrysin is currently at the animal and cell-culture level. No human clinical trials of isolated tectochrysin for any neurological indication have been published.
4.2 Anticancer Activity
Evidence level: Preclinical (cell-based and animal studies only — no human clinical trials identified).
Reviews of the pharmacological literature have signified the anticancer activity of tectochrysin on prostate cancer, human colon cancer, and breast cancer. The most detailed mechanistic work has been conducted in colon cancer cell lines. A study using HCT116 and SW480 human colon cancer cells investigated tectochrysin at concentrations of 1, 5, and 10 µg/ml in vitro, and in an in vivo study, a tectochrysin treatment dose of 5 mg/kg was injected into tumor-bearing mice. In the in vivo arm, tumor weights and volumes in mice were reduced when treated with tectochrysin.
In the combination oncology context, the purpose of one study was to evaluate the enhancing potency of tectochrysin when combined with cetuximab (an anti-EGFR monoclonal antibody) on human colon cancer cell growth; HCT116 and SW480 cells were treated with cetuximab at 30 µg/mL, tectochrysin at 5 µg/mL, or the combination. Cell proliferation was significantly inhibited by the combination of cetuximab and tectochrysin compared to treatment with either agent alone (combination index: 0.572 and 0.533, respectively). The combination index values below 1.0 indicate synergistic interaction, which is a meaningful preclinical finding.
With respect to multidrug resistance, research demonstrated that tectochrysin affected the proliferation of drug-resistant cancer cells, and the combination of tectochrysin with chemotherapeutic drugs exhibited substantial cytotoxicity. No human clinical trials of tectochrysin as an anticancer agent have been published. All anticancer evidence remains at the preclinical stage.
4.3 Anti-inflammatory Effects
Evidence level: Preclinical (cell-based and animal studies only — no human clinical trials identified).
Tectochrysin's anti-inflammatory activity has been documented across multiple organ systems and cell types. In macrophage-based models, tectochrysin inhibits ERK1/2 phosphorylation and sequentially suppresses downstream iNOS, TNF-α, and IL-6 transcription, as well as NO, TNF-α, and IL-6 protein levels in supernatant, without affecting MEK phosphorylation levels. In a murine model of allergic airway inflammation, tectochrysin attenuated Th2 cytokine (IL-4 and IL-5) production from antigen-stimulated murine splenocytes in vitro, decreased the expression of CD200R on basophils in peripheral blood of asthmatic mice, inhibited IL-4 secretion from IgE-sensitized RBL-2H3 cells, and enhanced catalase and glutathione peroxidase activities in lung tissues, demonstrating amelioration of allergic airway inflammation by suppressing Th2 response and oxidative stress.
In a periodontitis rat model, tectochrysin reduced alveolar bone loss, promoted new bone formation, and inhibited osteoclast formation; it decreased the number of inflammatory cells and the levels of IL-1β, IL-6, and TNF-α, indicating a reduction in inflammation. Tectochrysin restored the Arg-1/iNOS ratio, indicating M2 macrophage polarization, and inhibited the NF-κB pathway. All anti-inflammatory evidence is preclinical, with no reported randomized controlled trials in humans.
4.4 Hepatoprotective Effects
Evidence level: Preclinical (animal studies only).
Pharmacological studies have signified the biological application of tectochrysin in health sectors for the treatment of hepatic complications. In animal experiments, tectochrysin mitigated lipid peroxidation and increased the activities of antioxidant enzymes in rats with carbon tetrachloride-induced liver injury. The hepatoprotective mechanism appears to be primarily antioxidant in nature — attenuating oxidative damage — consistent with its general redox-modulating properties. No human studies have been published specifically examining tectochrysin's effects on liver function or disease.
4.5 Antimicrobial Activity
Evidence level: Preliminary in vitro only.
Anti-microbial activity of tectochrysin has been documented in the pharmacological literature. In cell-free and cell-based antimicrobial assays, tectochrysin has demonstrated activity against certain bacterial pathogens. Cayman Chemical's reference material data indicates that tectochrysin inhibits Pseudomonas aeruginosa at minimum inhibitory concentrations (MICs) in the range of 24–64 µg/mL, and also scavenges peroxyl radicals in a cell-free assay when used at concentrations of 1 and 10 µM. These values indicate moderate activity at best, and no clinical antimicrobial trials have been conducted.
4.6 Anti-osteoporotic and Bone-Protective Effects
Evidence level: Preclinical (animal studies only).
Anti-osteoporosis activity of tectochrysin has been discussed in the pharmacological literature. The periodontitis rat data reviewed above — in which tectochrysin reduced alveolar bone loss, promoted new bone formation, and inhibited osteoclast formation in periodontitis rats — provides an indirect but relevant preclinical basis for bone-protective claims. Separately, tectochrysin has demonstrated potential for the treatment of osteoporosis by promoting osteogenic differentiation and mineralization in MC3T3-E1 cells through the activation of extracellular signal-regulated kinase 1/2 (ERK1/2) pathways. No human clinical data for tectochrysin in osteoporosis or bone health has been identified.
4.7 Aging and Longevity
Evidence level: Invertebrate model organism (C. elegans) only — no mammalian or human clinical data.
In a 2020 study published in Biogerontology, researchers tested whether tectochrysin had an effect on aging in Caenorhabditis elegans; the results showed that tectochrysin could extend the lifespan of C. elegans by up to 21.0%, delay the age-related decline of body movement, improve high temperature-stress resistance and anti-infection capacity, and protect worms against Aβ1-42-induced toxicity. Tectochrysin could not extend the lifespan of the mutants from genes daf-2, daf-16, eat-2, aak-2, skn-1, and hsf-1, and it could increase the expression of DAF-16-regulated genes. The overall findings suggest that tectochrysin may have a potential effect on extending lifespan and age-related diseases. However, C. elegans findings do not translate directly to humans; this remains exploratory data.
4.8 Cardiovascular Effects
Evidence level: Preclinical (mouse models) — no human clinical data.
A 2026 study published in Frontiers in Pharmacology examined tectochrysin in angiotensin II-induced cardiac hypertrophy. In vivo and in vitro experiments demonstrated that tectochrysin inhibits activation of the STING-NFκB pathway, and use of the STING inhibitor H151 confirmed that STING is a critical mediator through which tectochrysin exerts its cardioprotective effects. The therapeutic efficacy of tectochrysin was assessed in the Ang II-induced mouse model using echocardiography, histopathological staining, and serological tests. This represents a very recent line of preclinical inquiry, with no human data available.
4.9 Antidiabetic and Metabolic Effects
Evidence level: Preclinical (cell and animal studies only).
Experimental animal data supports tectochrysin's antimicrobial, antioxidant, and metabolic functions. The pharmacological effects documented for Alpinia oxyphylla fruits (the primary source of tectochrysin) between 2018 and 2024 include neuroprotection, regulation of metabolic disorders, antioxidant activity, antiapoptosis, anti-inflammatory activity, antidiabetic activity, antihyperuricemia, antiaging, antidiuresis, immune regulation, anti-tumor activity, renal protection, hepatoprotection, and anti-asthma effects. No human clinical trials specifically attributing antidiabetic effects to isolated tectochrysin have been identified.
5. Body Systems and Health Areas Associated with Tectochrysin
Based on published preclinical research, tectochrysin has been studied in relation to the following body systems and health domains:
- Central Nervous System: Neuroprotection, memory and cognitive function, reduction of amyloid burden in Alzheimer's disease models, reduction of cholinesterase activity and oxidative stress in brain tissue.
- Immune System / Inflammation: Suppression of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), modulation of macrophage polarization toward the anti-inflammatory M2 phenotype, inhibition of Th2-driven allergic responses in asthma models, modulation of JAK/STAT signaling in rheumatoid arthritis models.
- Gastrointestinal System: Traditional anti-diarrheal use; modern data support anti-inflammatory effects in intestinal tissue; colon cancer cell cytotoxicity in vitro.
- Hepatic System: Hepatoprotection in carbon tetrachloride injury models via antioxidant mechanisms.
- Musculoskeletal / Bone: Inhibition of osteoclastogenesis and alveolar bone loss in periodontitis; promotion of osteogenic differentiation in cell models.
- Oncology: Cytotoxicity and apoptosis induction in colon, prostate, and breast cancer cell lines; reversal of multidrug resistance via ABCG2 and P-gp inhibition.
- Cardiovascular System: Inhibition of Ang II-induced pathological cardiac hypertrophy via STING/NF-κB pathway suppression.
- Respiratory System: Suppression of Th2-mediated allergic airway inflammation in murine asthma models.
- Aging Biology: Extension of lifespan and stress resistance in C. elegans via FOXO/DAF-16 transcription factor pathway.
6. Dosage Forms and Reported Dosages
No regulatory body (FDA, EMA, or equivalent) has approved tectochrysin as a therapeutic agent, and there is no established human dosing regimen. All dosage information below is drawn directly from published preclinical studies and is reported purely for scientific reference.
- Colon cancer (in vivo, mouse): In vitro treatment concentrations in SW480 and HCT116 cells were 1, 5, and 10 µg/mL; the in vivo mouse study used an injected dose of 5 mg/kg.
- Colon cancer combination study (in vitro): Tectochrysin was tested at 5 µg/mL (corresponding to approximately 1/3 of its IC50) in combination with cetuximab at 30 µg/mL (1/10 of IC50).
- Alzheimer's disease (in vivo, mouse, intracerebroventricular): AD mice received intracerebroventricular injection of tectochrysin at 140 µg/kg.
- Antimicrobial (in vitro): MICs against P. aeruginosa were in the range of 24–64 µg/mL; peroxyl radical scavenging activity was demonstrated at concentrations of 1 and 10 µM in a cell-free assay.
The route of administration in published studies varies: intracerebroventricular injection (in the Alzheimer's mouse study), intraperitoneal injection (in asthma models), and in vitro cell culture exposure. Oral bioavailability studies of isolated tectochrysin in humans are absent from the published literature. Flavonoids in A. oxyphylla show low plasma levels after oral administration because they mainly form mono-glucuronide metabolites, making measurement of free flavonoids in plasma difficult. This is a significant limitation for oral supplementation scenarios.
7. Safety Considerations and Drug Interactions
Reported Toxicological Profile
Formal human safety data for isolated tectochrysin are absent. However, preclinical safety signals have been assessed in the research literature. The relatively low toxicity of tectochrysin and 6-prenylchrysin, along with their efficient sensitization of cell growth to mitoxantrone, made these compounds promising for future potential use in clinical trials. Complementary to this, although tectochrysin has not been found to possess potential toxicity in preclinical studies, given the unknown human exposure-response relationship, potential off-target effects, differences in STING biology between rodents and humans, and the necessity for further medicinal chemistry optimization, it is essential to conduct pharmacokinetic, pharmacodynamic, and bioavailability studies, as well as long-term safety tests, before broader application of tectochrysin. This represents the current scientific consensus regarding its safety status.
Drug Transporter Interactions
A notable safety and pharmacokinetic interaction consideration arises from tectochrysin's established activity as an inhibitor of drug efflux transporters. Tectochrysin has been identified as a potent inhibitor of ABCG2 — also known as breast cancer resistance protein (BCRP). Inhibition of ABCG2 could potentially alter the systemic exposure to co-administered drugs that are ABCG2 substrates (including several chemotherapeutics, certain statins, and antiretrovirals), leading to increased plasma concentrations and possible toxicity. Tectochrysin also noncompetitively inhibits the efflux of rhodamine 123 and doxorubicin through P-gp, without being a P-gp substrate itself. This dual transporter-inhibitory profile (ABCG2 and P-gp) is a significant pharmacological interaction risk that has not been characterized in human subjects.
Bioavailability Limitations
Flavonoids in A. oxyphylla showed low plasma levels after oral administration because they mainly form mono-glucuronide metabolites; there are only a few analytical methods reporting on the active constituents from A. oxyphylla in biological samples. In a pharmacokinetic study comparing normal rats and dementia-model rats, both the AUC and Cmax of tectochrysin were remarkably increased in dementia rats compared to normal rats after oral administration — indicating that disease state may substantially alter the absorption or first-pass metabolism of tectochrysin. The implications of this differential for dosing and safety in human disease populations are entirely unknown at this time.
Absence of Clinical Safety Data
There are no reported Phase I, II, or III clinical trials for tectochrysin as an isolated compound. Accordingly, maximum tolerated dose, therapeutic window, adverse event profile, and drug-drug interactions in humans remain completely uncharacterized. The complete absence of human clinical data means that any safety characterization beyond what is noted above for the preclinical or mechanistic literature cannot be made with scientific rigor.
8. Summary of Evidence Strength
The totality of scientific evidence for tectochrysin as of 2026 is entirely preclinical. The compound has demonstrated a broad range of biological activities in cell culture and animal model systems, including antioxidant, anti-inflammatory, anticancer, neuroprotective, hepatoprotective, antimicrobial, anti-osteoporotic, cardioprotective, and antiaging effects. Tectochrysin is an important class of dietary flavonoids present in foods and fruits, with anti-tumor, anti-Alzheimer's, and antimicrobial activities documented in preclinical medicine. However, no human clinical trials have been published for any indication involving isolated tectochrysin. Evidence from C. elegans (invertebrate models), rodent studies, and in vitro cell experiments, while mechanistically informative, cannot be directly extrapolated to therapeutic efficacy or safety in humans. Any characterization of tectochrysin as a treatment for any human disease or condition at this stage would be premature and unsupported by the available evidence.
References
Go back